Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sanofi (GB:0O59)
LSE:0O59
Earnings Data
Report Date
Jan 30, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
1.41Last Year’s EPS
1.66Same Quarter Last Year
Strong Buy
Based on 12 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 31, 2018
|% Change Since: 0.69%
|Next Earnings Date:Jul 31, 2018
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment overall, driven by strong sales growth, successful product launches, and significant R&D advancements. Despite some challenges like gross margin pressure and increased expenses, the company's strategic focus on innovation and market expansion supports a strong outlook.Company Guidance
During the Q4 and full year 2024 earnings call, Sanofi provided robust guidance and reported strong financial performance. The company achieved a 10.3% increase in net sales for Q4, reaching €10.6 billion, and an 11.3% increase for the full year, totaling €41.1 billion, driven by new product launches and Dupixent's success. Gross margin stood at 74.3% for Q4 and 75.7% for the year. R&D expenses rose by 14.6% to €7.4 billion, reflecting pipeline investment, while SG&A expenses grew by 4.5%. Sanofi exceeded its EPS guidance, with business EPS growing by 4.1% to €7.12. Looking ahead to 2025, the company anticipates mid-to-high single-digit sales growth at constant exchange rates, with a low double-digit EPS increase, excluding share buyback and foreign exchange impacts. Sanofi plans a €5 billion share buyback and expects a positive currency impact on both sales and EPS.Double-Digits Sales Growth
Sanofi achieved double-digits sales growth for the third consecutive quarter, driven by vaccines, Dupixent, and new pharma launches. Net sales increased by 10.3% in Q4 2024 and 11.3% for the full year at constant exchange rates.
Beyfortus Blockbuster Achievement
Beyfortus achieved blockbuster status in its first full year of sales, reaching close to €1.7 billion in 2024. The product expanded RSV protection to over 6 million babies globally.
R&D and Pipeline Advances
Positive Phase 3 results for drugs like fitusiran, rilzabrutinib, and tolebrutinib were reported, with potential launches anticipated in 2025. The pipeline also saw 21 regulatory submissions and 14 approvals.
Dupixent Exceeds Sales Target
Dupixent exceeded its €13 billion sales target, driven by strong global demand. In Q4, Dupixent sales grew by 16%.
Vaccines Business Record
The vaccines segment crossed the €8 billion milestone, up by 13.5%, driven by Beyfortus and a resilient flu franchise.
Access to Medicine Index Improvement
Sanofi improved its ranking in the Access to Medicine Index from eighth to third place, reflecting its commitment to global health.
---
GB:0O59 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:0O59 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Jan 30, 2025 | €101.61 | €102.88 | +1.25% |
| Oct 25, 2024 | €98.52 | €99.19 | +0.67% |
| Jul 25, 2024 | €92.17 | €77.73 | -15.67% |
| Apr 25, 2024 | €84.53 | €87.72 | +3.77% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Sanofi (GB:0O59) report earnings?
Sanofi (GB:0O59) is schdueled to report earning on Jan 30, 2025, TBA Not Confirmed.
What is Sanofi (GB:0O59) earnings time?
Sanofi (GB:0O59) earnings time is at Jan 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Sanofi stock?
The P/E ratio of Sanofi is N/A.
What is GB:0O59 EPS forecast?
GB:0O59 EPS forecast for the fiscal quarter 2024 (Q4) is 1.41.
---